NO20033910L - Fremgangsmåte og doseringsform for behandling av tumorer ved administreringav tegafur, uracil, folinsyre, paclitaxel og karboplatin - Google Patents

Fremgangsmåte og doseringsform for behandling av tumorer ved administreringav tegafur, uracil, folinsyre, paclitaxel og karboplatin

Info

Publication number
NO20033910L
NO20033910L NO20033910A NO20033910A NO20033910L NO 20033910 L NO20033910 L NO 20033910L NO 20033910 A NO20033910 A NO 20033910A NO 20033910 A NO20033910 A NO 20033910A NO 20033910 L NO20033910 L NO 20033910L
Authority
NO
Norway
Prior art keywords
tegafur
carboplatin
paclitaxel
uracil
tumors
Prior art date
Application number
NO20033910A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033910D0 (no
Inventor
Jafferhusen A Ajani
Steven E Benner
Terry S Dugan
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20033910D0 publication Critical patent/NO20033910D0/no
Publication of NO20033910L publication Critical patent/NO20033910L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20033910A 2001-03-06 2003-09-04 Fremgangsmåte og doseringsform for behandling av tumorer ved administreringav tegafur, uracil, folinsyre, paclitaxel og karboplatin NO20033910L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27357701P 2001-03-06 2001-03-06
PCT/US2002/006262 WO2002076459A1 (en) 2001-03-06 2002-03-04 Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin

Publications (2)

Publication Number Publication Date
NO20033910D0 NO20033910D0 (no) 2003-09-04
NO20033910L true NO20033910L (no) 2003-10-23

Family

ID=23044526

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033910A NO20033910L (no) 2001-03-06 2003-09-04 Fremgangsmåte og doseringsform for behandling av tumorer ved administreringav tegafur, uracil, folinsyre, paclitaxel og karboplatin

Country Status (20)

Country Link
US (1) US6770653B2 (cg-RX-API-DMAC7.html)
EP (1) EP1368034A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005506294A (cg-RX-API-DMAC7.html)
KR (1) KR20030081496A (cg-RX-API-DMAC7.html)
BR (1) BR0207443A (cg-RX-API-DMAC7.html)
CA (1) CA2439676A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20032266A3 (cg-RX-API-DMAC7.html)
EE (1) EE200300429A (cg-RX-API-DMAC7.html)
HR (1) HRP20030801A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0303466A3 (cg-RX-API-DMAC7.html)
IL (1) IL157357A0 (cg-RX-API-DMAC7.html)
IS (1) IS6925A (cg-RX-API-DMAC7.html)
MX (1) MXPA03007989A (cg-RX-API-DMAC7.html)
NO (1) NO20033910L (cg-RX-API-DMAC7.html)
PL (1) PL363967A1 (cg-RX-API-DMAC7.html)
RU (1) RU2284184C2 (cg-RX-API-DMAC7.html)
SK (1) SK10602003A3 (cg-RX-API-DMAC7.html)
WO (1) WO2002076459A1 (cg-RX-API-DMAC7.html)
YU (1) YU69903A (cg-RX-API-DMAC7.html)
ZA (1) ZA200306541B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素-743在制备用于治疗肿瘤的药剂中的应用
JP4610481B2 (ja) 2003-03-14 2011-01-12 大鵬薬品工業株式会社 抗腫瘍効果増強剤及び抗腫瘍剤
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
JP4554684B2 (ja) * 2004-10-26 2010-09-29 ファルマ・マル・エス・アー, ソシエダッド・ユニペルソナル 抗癌治療
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SI2301531T1 (sl) 2005-02-18 2018-11-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2008202078B2 (en) * 2007-10-10 2012-05-31 Wellkey Holdings Limited Stability of secondary metabolite mass production through synchronized plant cell cultures
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Et−743治療のための予後分子マーカー
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
CN105147613A (zh) 2010-03-29 2015-12-16 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
EP2575804A4 (en) 2010-06-04 2013-10-23 Abraxis Bioscience Llc METHOD FOR THE TREATMENT OF PANCREASCRE
CA2983411C (en) * 2015-04-22 2023-02-21 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
JP7008025B2 (ja) 2016-08-31 2022-01-25 富士フイルム株式会社 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
RU2646450C1 (ru) * 2017-05-11 2018-03-05 Владимир Михайлович Курусин Способ лечения предраковых и ранних стадий раковых заболеваний желудка
AU2018404329B2 (en) 2018-01-29 2021-09-09 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4328229A (en) 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en) 1991-09-05 1996-07-09 Taiho Pharmaceutical Company, Ltd. Antitumor potentiator and antitumor composition
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
RU2194541C1 (ru) * 2001-07-13 2002-12-20 Научно-исследовательский институт онкологии Томского научного центра СО РАН Способ комбинированного лечения больных местнораспространенным раком желудка

Also Published As

Publication number Publication date
HUP0303466A2 (hu) 2004-01-28
MXPA03007989A (es) 2003-12-04
KR20030081496A (ko) 2003-10-17
CA2439676A1 (en) 2002-10-03
US6770653B2 (en) 2004-08-03
RU2003129527A (ru) 2005-03-10
WO2002076459A1 (en) 2002-10-03
RU2284184C2 (ru) 2006-09-27
NO20033910D0 (no) 2003-09-04
CZ20032266A3 (cs) 2004-02-18
HRP20030801A2 (en) 2004-08-31
SK10602003A3 (en) 2004-10-05
BR0207443A (pt) 2004-04-06
IL157357A0 (en) 2004-02-19
ZA200306541B (en) 2004-11-22
EE200300429A (et) 2003-12-15
YU69903A (sh) 2006-08-17
US20020173482A1 (en) 2002-11-21
HUP0303466A3 (en) 2005-02-28
EP1368034A1 (en) 2003-12-10
IS6925A (is) 2003-08-22
PL363967A1 (en) 2004-11-29
JP2005506294A (ja) 2005-03-03

Similar Documents

Publication Publication Date Title
NO20033910D0 (no) Fremgangsmåte og doseringsform for behandling av tumorer ved administreringav tegafur, uracil, folinsyre, paclitaxel og karboplatin
WO2003080582A3 (de) Fredericamycin-derivate
WO2002085857A3 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
IL164135A (en) 4-anilino quinazoline derivatives as antiproliferative agents, process for their preparation, pharmaceutical compositions containing such derivatives and use thereof for the preparation of medicaments for the treatment of cancer
WO2005110994A3 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
ATE454378T1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
EA200401318A1 (ru) Производные хинолинона
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
NO20041277L (no) Farmasoytiske preparater for behandling av astma.
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
DK1200412T3 (da) Antiproliferative imidazolforbindelser
DE50310516D1 (de) Fredericamycin-derivate
ATE341545T1 (de) Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
WO2004071382A3 (en) Substituted heterocycles
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
WO2005105094A3 (en) Cancer treatment method
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
EA200501233A1 (ru) 4-аминопиримидин-5-он
ATE429230T1 (de) Chinazoline derivative und ihre anwendung in der krebsbehandlung
ATE336489T1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
NO20034690L (no) Fremgangsmåte for behandling av tumorer ved administrering av tegafur, uracil, folinsyre og cyklofosfamid

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application